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Effect of long-term low dose prednisolone administration 
on bone mineral density: Relating to non-compliant women 
with rheumatoid arthritis 
 
Abstract 
Background: Long-term treatment of rheumatoid arthritis (RA) with prednisolone (PRED) 
is associated with bone mineral density (BMD) loss. This study aimed to determine the 
status of BMD in non-compliant women who used PRED alone for RA. 
Methods: Non-adherent RA taking < 7.5 mg daily PRED without DMARDs for > 6 
months, and RA patients taking methotrexate +PRED (RA control) were compared with 
age-matched non-RA controls. BMD was measured by dual energy x-ray absorptiometry 
(DXA) method and osteoporosis (OP) was diagnosed by WHO criteria. Influence of PRED 
on RA bone mass, and the risk of OP in RA  was assessed by comparing PRED users RA 
and RA control,versus non-RA controls. 
Results: Sixty-four PRED user RA, 39 RA controls and 111 non RA-controls, with 
respective mean (±SD) age of 52±11; 8, 51±11; and 52±7.5 years (P=0.91) were studied. 
Median duration of treatment in PRED users and RA control was 2.5 and 4 years, 
respectively. BMD g/cm
2 
at the femoral neck (FN-BMD) and lumber spine (LS-BMD) in 
PRED users and RA control was significantly lower than non-RA control (P=0.001). The 
prevalence of OP at either FN or LS in both RA groups was significantly higher than 
controls (P=0.001). In PRED users, the risk of OP increased by OR=4.9, P=0.001) and in 
RA controls by OR=1.7 (P=0.20). The risk of OP in PRED user RA was 2.89 times 
(P=0.014) greater than RA controls. 
Conclusions: These findings indicate significantly lower BMD, and higher prevalence of 
osteoporosis in non-compliant women with RA taking low-dose PRED alone for a median 
period of 2.5 years, as compared with patients taking standard treatment comprising 
methotrexate +PRED. 
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Rheumatoid arthritis (RA) is an inflammatory arthritis associated with bone loss and 
osteoporosis. Bone loss arises as a consequence of inflammatory process, impaired 
physical activity and inadequate treatment (1-4). The magnitude of bone loss varies 
according to severity of the disease and extent of suppression of inflammatory process 
with appropriate treatment using disease-modifying anti-rheumatic drugs (DMARDs) (5). 
Currently, treatment of RA emphasizes on early and regular use of anti-inflammatory 
drugs particularly low dose methotrexate (MTX) with or without low-dose prednisolone 
(PRED) directing to decrease disease activity and remission achievement (6). Adherence 
to prescribed medications and following treatment regimen has a major role in 
improvement and outcome (7, 8). Non-adherence to prescribed medications is expected to 
be associated with continuous disease activity and greater disability leading to greater bone 
loss.  
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The percentage of RA patients following prescribed 
medications varies across different study populations (9, 10). 
In a randomly selected sample of 228 patients with RA, 32-
40% of patients did not adhere to their DMARD prescription 
(8)11. In one study consisted of 788 randomly selected RA, 
only 64.3% of patients adhered to MTX. In this study, 
DAS28 score was significantly greater  in the group treated 
with MTX in single therapy as compared with the group who 
were treated with glucocorticoid alone (10). In one study of 
108 RA, 39% of the patients were non-compliant with their 
treatment regimen varying from occasional to complete 
failure to take prescribed medications (12). 
In RA patients, adherence rate to oral MTX and steroid 
ranges from 58-71% (12). Among the non-compliant RA 
patients, adherence to take low-dose PRED seems to be 
greater than other anti-inflammatory drugs due to its rapid 
symptomatic action on joint pain and tenderness (13). Non-
adherent steroid user RA patients are at greater risk of bone 
loss and osteoporosis as compared to adherent RA patients 
who follow conventional treatment containing MTX or other 
DMARDs in combination with PRED. As glucocorticoids 
exert some disease-modifying effect on bone due to its anti-
inflammatory effect, and thus may partly compensate 
adverse effects (13). Nevertheless, glucocorticoid therapy is 
independently associated with increased risk of bone mineral 
density (BMD) loss in the hip and spine (14). In chronic 
users, cumulative dose of glucocorticoid causes further bone 
loss and increases the risk of osteoporosis at least two times 
(15). Despite several published studies regarding 
complications of long-term glucocorticoids therapy in RA, 
nevertheless BMD status in non-compliant steroid user RA 
has not been investigated yet. This study was performed to 
determine the influence of low-dose PRED in non-adherent 
RA patients who used low-dose steroids as the sole drug for 
treatment of disease without any DMARDs for prolonged 
period.  
 
 
Methods 
The patients of this case- control study were selected 
consecutively according to inclusion criteria among RA the 
patients who referred to the outpatient rheumatology clinic in 
Babol for treatment evaluation over a one-year- period in 
Babol, Iran. The diagnosis of RA was confirmed by the 1987 
American College of Rheumatology revised criteria (16). 
Data were provided with respect to adherence to prescribed 
medications, type of medications and duration of treatment 
via a face-to-face interview. Non-adherent patients who used 
low-dose PRED (< 7.5 mg/day) without DMARDs longer 
than 6 months as the sole drug for treatment of RA were 
considered as steroid user group (RA cases) and adherent 
RA who followed the standard treatment including MTX 
with or without low-dose PRED, were considered as control 
(RA control).  
Exclusion criteria included psoriatic arthritis, systemic 
lupus erythematous, undifferentiated arthritis, and the 
presence of coexistent conditions leading to altered bone 
metabolism. A group of age-matched non-RA patients were 
also selected as non-RA controls among women presented to 
the same clinic for bone densitometry. A similar exclusion 
criterion was also applied for the control group. BMD gr/cm
2 
was assessed in the femoral neck (FN) and lumbar spine 
(LS) regions by dual x-ray absorptiometry (DXA). Sample 
size was estimated to detect a 20% difference between the 
patients and the control group. Based on our earlier study 
(6), thus 30 patients for each group would be adequate to 
detect such difference with power of 80% and confidence 
level of 95%. However, we included further patients to 
compensate the missing data. The results of bone 
densitometry were compared with the reference data 
supplied by the manufacturer and expressed as BMD g /cm
2
, 
BMD T-score, BMD Z-score for each measurement site. The 
proposal of this study was approved by the Ethics 
Committee of Babol University of Medical Sciences, Babol, 
Iran. The primary objective of this study was to determine 
the influence of long-term low-dose PRED on RA bone mass 
by comparison of steroid user RA and RA controls with age-
matched non -RA control as regards mean BMD g /cm
2 
differences and frequency of osteoporosis. The secondary 
objective was to determine the risk of osteoporosis in each 
group of RA by calculating odds ratio (OR) with 
corresponding 95% confidence interval (95% CI). Diagnosis 
of osteoporosis was confirmed by the WHO criteria (17) 
(BMD-T -score less than - 2.5) and the frequency of 
osteoporosis was determined at either FN or LS based on the 
lowest T -score (T-score < 2.5) of the measured skeletal sites 
as proposed by the International Society for Clinical 
Densitometry (one diagnostic category) (18). Distribution of 
all variables was determined by Kolmogorov- Smirnov test. 
Nonparametric Mann-Whitney U test and independent t test 
was used for comparison of quantitative variables with 
skewed or normal distributions, respectively.   
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Results 
Sixty-four steroid  user RA patients with mean (±SD) age 
of 52±11.8 years, 39 RA controls with mean (±SD) age of 
51±11 years, and 111 non-RA controls with mean (±SD) age 
of  52±7.5 years  (P=0.91) were studied. Median disease 
duration (DD) in steroid users and RA controls was 6 (0.16-
40) and 9 (1-21) years (P=0.001) and median duration of 
treatment was 2.5 (0.12-20) and 4(0.16-10) years, 
respectively (P=0.001) (table 1). The two groups of RA were 
compared with regard to percentage of RF (P=0.55) and 
prevalence of anti-cyclic citrullinated peptide antibody 
positivity (P=0.35). FN- BMD g /cm
2 
and LS- BMD g /cm
2 
in both RA groups were significantly lower than non-RA 
controls (P=0.001 for both).The BMD g /cm
2 
at both sites, in 
steroid user RA was significantly lower than RA controls 
(P=0.001) (table 1). Compared with non-RA controls, The 
BMD at FN, in steroid users was lower than RA controls 
(data not shown) (24.3% vs 16%, P=0.74). Corresponding 
values for LS- BMD g /cm
2 
between steroid users and RA 
controls as compared with non-RA controls were 12.9% and 
8.4% (data not shown) respectively, none (P= 0.29). 
 
Osteoporosis at either FN or LS was observed in 36 
(56,2%) in steroid user patients versus 12 (30.8%) patients in 
RA control group (0.001). In logistic regression analysis 
after adjustment for menopausal duration, compared to non-
RA control, the risk of osteoporosis at either FN or LS 
increased by odds of 4.90 (95% CI, 2.50-9.65. P=0.091) in 
steroid users RA and 1.7(95%CI, 0.75-3.86, P=0.20) in RA 
controls (table 1). Risk of osteoporosis at FN or LS in steroid 
user RA was 2.89 times greater than RA controls 
(OR=2.89.95% CI, 1.24-6.7, P=0.014). 
 
Table 1. Characteristics of women rheumatoid arthritis (RA) who were treated with long-term low-dose prednisolone 
monotherapy (steroid users), or conventional drugs including combination of low-dose methotrexate and low-dose 
prednisolone compared with age-matched non-RA controls 
Characteristics of patients Standard therapy≠ 
(RA controls) 
Steroid users (RA  cases)҂ Non-RA Controls P-value 
No 39 64 111  
Age (yrs) 50.6±11.4 52.5±11.8 52±7.5 0.91 
Disease duration (years) 
median( range)  
9 (1-22) 6 (0.16-40) - 0.001 
Treatment duration (years) 
Medan (range) 
4 (0.16-10) 2.5 (0.12-20) 0.001 0.001 
RF positivity, no (%)
α
 27 (69.8) 44 (69.2)  0.55 
Anti-CCP positivity, no(%)
β 
 30 (76.9) 50 (82)  0.35 
Methotrexate, no (%) 39 (100) 0 (0%)  0.001 
Low-dose prednisolone, no (%) 39 (100) 42 (67.7)  0.001 
OP 12 (30.8) 35 (54.7) 23 (20.7)  
FN-BMD
¥
 0.73±0.10 0.68±.13 0.87±0.16 0.001 
LS-BMD
¥
 0.85±0.15 0.81±0.15 0.93±0.16.  
Osteoporosis at either FN or LS
α
 12 (30.8) 36 (56.25) 23 (20.7) 0.001 
Risk of osteoporosis 
€ 
 1.7 (0.75-3.8) 4.9 (2.5-9.6) 1  
≠:  RA patients treated with combination of low-dose prednisolone and methotrexate  
҂: RA patients treated with low-dose prednisolone alone <7.5 mg/daily for prolonged period  
Α: Rheumatoid factor        β: Anti-cyclic citrullinated peptide antibody          ¥ Femoral neck (FN) and lumbar spine (LS) bone mineral density (BMD)       
 €  Risk of osteoporosis at either FN or LS by logistic regression analysis 
 
Discussion 
The results of this study indicated that patients with RA 
have lower BMD g /cm
2 
compared with age-matched non -
RA controls.  Non-compliantt patients with RA who used  
 
 
low-dose PRED as the sole drug therapy for a median  
duration of 2.5  years had significantly lower bone mass as 
compared with age-matched controls, as well as with RA 
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patients, who followed combination of low-dose PRED and 
MTX for a median duration of 4 years. In this study, the 
BMD in RA control, in spite of the longer disease duration 
than steroid user RA was higher, which should be attributed 
to synergetic effect of MTX and low-dose PRED (19).  
Compared with non -RA controls, in both RA groups, the 
mean BMD difference at the FN was higher than lumbar 
spine. This issue indicate that, in RA, bone loss at the 
femoral neck is greater than lumbar spine, which should be 
attributed to synovitis of hip (14). 
The impact of low -dose PRED with or without MTX on 
RA bone mass has been addressed in several studies (20-25). 
Current data indicate that prolonged corticosteroid therapy is 
associated with high prevalence rate of osteoporosis (23, 24). 
Combination of steroids and DMARDs exerts beneficial 
effect in preserving greater bone mass (21, 26, 28-30). The 
findings of this study are in contrast with a few previous 
studies which have found no beneficial effect of MTX alone 
or in combination with low-dose PRED in preserving BMD  
(8, 31, 32). Nonetheless, duration of treatment in these 
studies was shorter than the present study.  
A systematic review of randomized controlled trials or 
cross- over trials demonstrated that, the addition of low dose 
PRED to the standard therapy can substantially reduce the 
rate of bone erosion in RA, or reduce bone erosions or 
disease progression (32). Nevertheless, with regard to bone 
mass status, the outcome of RA patients on long-term 
immunotherapy with low -dose PRED has not been 
compared with standard therapy including low- dose PRED 
and MTX. Sambrouk et al. in a study of 84 RA patients, 
found   a significant BMD loss at FN and LS regions in both 
PRED-users and non-users RA .Percentage of BMD loss 
over an average period of 89.6 months did not differ between 
the two groups and the authors concluded that low dose oral 
corticosteroids did not increase the risk of generalized 
osteoporosis in patients with rheumatoid arthritis (33).  
The beneficial effects of corticosteroids in RA arise with 
decreasing synovitis, bone erosion, joint pain and increasing 
physical activities.  In one study, RA patients who  failed  to 
stop PRED due to recurrence of joint pain, after two years, 
had no greater bone loss compared with those who 
discontinued , but in contrast,  the value of BMD Z score in 
these patients was greater (20). The benefits of low- dose 
PRED in compensating the negative effect of inflammation 
on bone mass is clearer in early RA, which exerts a bone 
mass preserving effect particularly in the hip joint (24, 34). 
In addition, combination of low-dose PRED and DMARDs 
prevent or retard progression of radiographic erosions (26). 
The extent of contribution of steroid therapy in the 
development of osteoporosis in non-compliant RA is 
difficult to determine. Since, not only the inflammatory 
process, but other associated factors of osteoporosis may 
also cause low bone mass in RA (35-37). Furthermore, 
several factors like long disease duration, low to moderate 
disease activity and liver disease are associated factors of 
osteoporosis in RA, these factors themselves may decrease 
patient's compliance (38).  
Patients with RA are required to take multiple drugs for 
prolonged period of time. While self-efficacy encourages 
patients to follow treatment (26), fear of drugs toxicity is an 
important factor of non-compliance to treatment (39). In one 
prospective study of RA, over three years, 35.7% of patients 
were consistently compliant and 23.8% were persistently 
non-compliant to treatment. Older age, female sex and 
disability, significantly increased compliance (40) in 
addition, drug dosage, age of onset, affect the levels of 
adherence. In one study, the rates of compliance with 
treatment varied from 73% for etanercept, and 59% for 
MTX, to 6% for glucocorticoid (41) in a similar study, two 
years retention rate of MTX for psoriatic arthritis and RA 
were 65% and 66%, respectively (40). By lengthening of 
duration treatment, the rate of adherence to MTX in RA 
decreased from 68.2% in one year to 49.8% two years after 
the newly diagnosed elderly RA (19). 
A significant benefit of MTX plus low-dose PRED on 
FN bone mass in RA should be attributed to anti-
inflammatory effect of corticosteroid against hip synovitis. 
Synovial inflammation of hip joint has a major contribution 
in the development of radiologic damage and osteoporosis in 
FN region (14). 
The findings of this study should be considered with 
limitations. In this study, the data regarding disease activity 
score were not provided before and after the treatment. 
Disease activity correlates with bone loss (14, 30). 
Furthermore, information concerning other conventional risk 
factors of osteoporosis (35, 36, 37) have not been collected. 
Yet, these factors are expected to be distributed similarly 
across the comparison groups, so the results might be 
confound minimally. Factors such as magnitude of BMD 
changes with treatment of RA, age at onset of RA may also 
affect the results (42, 43). Additionally, coexistence of RA 
with osteoarthritis falsely increases BMD, particularly at the 
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lumbar spine and may cause underestimation of osteoporosis 
(44). The distribution of osteoarthritis is expected to be 
similar across the study groups and the results with minimal 
confounding effect. 
In conclusion, this study indicates that non-compliant RA 
who used only low-dose PRED for treatment of RA, has 
significantly lower BMD and higher prevalence of 
osteoporosis, as well as greater risk of osteoporosis as 
compared with RA patients on conventional treatment 
comprising MTX and PRED. These findings indicate that 
low-dose PRED in combination with MTX exerts BMD 
preserving effect. 
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